ClinicalTrials.gg
CompletedNCT07931053Updated Nov 16, 2026

Use of mHealth Application and Education to Increase Appropriateness of Thromboprophylaxis in Patients With Cancer

An interventional study of mHealth application and Education. Guideline review in Cancer, Health Services Research and mHealth Application, sponsored by Universidad Miguel Hernandez de Elche. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Universidad Miguel Hernandez de Elche · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Jan 2024, registered Oct 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigators will use a mHealth application to evaluate the risk of thrombosis and bleeding in patients with cancer.

Read the detailed description

This information will be shared with the patients to make an informed decision of using low molecular weight prophylaxis with heparin in case of high risk thrombosis a low-moderate risk of bleeding

02

Conditions studied

  • Cancer
  • Health Services Research
  • mHealth Application
  • Thromboprophylaxis

Browse trials for

Keywords

  • mHealth Application
  • Education
  • Thromboprophlasis in solid tumors
  • Appropiateness use
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 180 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Universidad Miguel Hernandez de Elche is the lead sponsor of 88 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older, and
  • Recent diagnosis of a solid tumor or disease progression after partial or complete remission, and.
  • Starting a new course of systemic anticancer therapy (chemotherapy, targeted therapy, hormone therapy, or immunotherapy) planned for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • High risk of bleeding (e.g., advanced liver disease with coagulopathy), or
  • under 3 months, or
  • Hematologic , or
  • Estimated below 30 mL/min/1.73 m², or
  • count below 50,000/mm³, or
  • Body weight below 40 kg, or
  • Current anticoagulant use.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • No intervention
    Control group (preintervention)

    Inclusion criteria: * Age 18 or oler * Recent diagnosis of solid tumor or disease progression after partial or complete remission. * Starting a new course of systemic anticancer therapy-chemotherapy, targeted therapy, hormone therapy, or immunotherapy-planned to last at least 3 months. Exclusion criteria: * High risk of bleeding (e.g., advanced liver disease with coagulopathy) * Life expectancy of less than 3 months * Hematologic malignancy * Estimated glomerular filtration rate below 30 mL/min/1.73 m² * Platelet count below 50,000/mm³ * Weighed less than 40 kg * Currently receiving anticoagulation. In the preintervention period, The investigators reviewed the electronic medical records of patients with a recent cancer diagnosis who were seen between January and June 2024.

  • Active comparator
    postintervention

    After using the mHealth application, the treating physician made the final decision regarding use of thromboprophylaxis after considering risk of thromboembolic disease, bleeding risk, renal function, drug interactions, and patient preferences. Postintervention period. For patients with cancer seen between January and June 2025, the investigators collected the same variables from the electronic medical records as in the preintervention period. The investigators selected the same calendar months to control for seasonality and enhance comparability between periods

    Other: mHealth application · Other: Education. Guideline review

Interventions

  • OthermHealth application

    Physicians from the Internal Medicine and Oncology divisions attended a 2-hour session reviewing current guidelines for thromboprophylaxis in patients with cancer, followed by training on the mHealth TEVAPP application. TEVAPP is a web-based calculator of venous thromboembolism (VTE) risk scores for patients with cancer, developed by the Spanish Society of Medical Oncology (SEOM) (Spain; https://tevapp.es/; accessed December 15, 2024). The application was used to support clinical decision-making by integrating available clinical, laboratory, and treatment information at the initial visit before the initiation of a new systemic regimen.

  • OtherEducation. Guideline review

    TEVAPP is a web-based calculator of VTE risk scores for patients with cancer, developed by SEOM (Spain; https://tevapp.es/; accessed December 15, 2024). It was used to support clinical decisions by integrating available clinical, laboratory, and treatment information at the initial visit before a new systemic regimen

06

What researchers measure

Primary outcomes

  1. Proprtion of patients with appropriate thromboprophylaxis use

    The primary outcome was the proportion of patients with appropriate prescription of thromboprophylaxis from the first medical oncology visit in the pre- and postintervention periods. The appropriateness of thromboprophylaxis was determined according to clinical practice guideline recommendations. Thromboprophylaxis was considered appropriate when weight-adjusted enoxaparin was prescribed for patients at intermediate or high thrombotic risk (6-month VTE probability \>8%) and low bleeding risk, in the absence of other contraindications. Low bleeding risk was defined as an IMPROVE score \<7 for patients hospitalized within the previous 30 days, or a Hokusai score \<3 for nonhospitalized patients. In the version of TEVAPP used, the latter corresponded to fewer than 60% of bleeding risk factors. Withholding thromboprophylaxis was considered appropriate for patients at low thrombotic risk or with contraindications to anticoagulation.

    Time frame: From first visit to oncology clinic up to three month of follow up

Secondary outcomes

  1. Incidence of venous thromboembolic disease

    The investigators compared the incidence of VTE disease in the pre- and postintervention periods. VTE was suspected based on clinical symptoms and signs and confirmed with objective testing. The diagnostic approach includes assessment of pretest clinical probability, selective D-dimer testing, and imaging. Suspected DVT: Clinical probability is estimated using the 2-level Wells score. Patients with a likely score (≥2 points) should undergo proximal leg-vein compression ultrasonography, preferably with Doppler assessment; D-dimer may be used selectively when ultrasound is negative or clinical probability is low. Suspected PE: Clinical probability is estimated using a validated score such as the Wells score. Definitive diagnosis is usually made with CT pulmonary angiography (CTPA) or a ventilation-perfusion scan.

    Time frame: From first visit the the Oncology Clinic up to three months of follow-up

  2. Incidence of bleeding

    The investigators compared the bleeding events in the pre- and postintervention periods classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical site or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome), or bleeding associated with a hemoglobin decrease of ≥2 g/dL or transfusion of ≥2 units of whole blood or packed red blood cells. Clinically relevant non-major bleeding was defined as overt bleeding not meeting major bleeding criteria but requiring hospitalization, medical or surgical intervention, or interruption or modification of anticoagulant therapy

    Time frame: From first visit the the Oncology Clinic up to three months of follow-up

  3. Incidence of death

    The investigators compared all-cause mortality in the pre- and postintervention periods. All-cause mortality was defined as death from any cause occurring during the study follow-up period.

    Time frame: From first visit the the Oncology Clinic up to three months of follow-up

07

Study locations

1 site
  • Hospital Marina Baixa
    Villajoyosa, Alicante 03570, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Upon reasonable request we can provide a copy of the database with patient de-identification

Supporting information: Study protocol, Statistical analysis plan

Time frame: October 2026, to October 2027

Access criteria: Javier Ena, MD. Personal computer

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Sep 2025, 20 months.

Of 1,986 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 20 months is below that.

Counting every sponsor, half of 2,061 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 12, 2026
StartActual
Jan 1, 2024
Primary completionActual
Sep 30, 2025
CompletionActual
Dec 30, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionIncidence of bleeding: how it is measured was reworded
  • DescriptionIncidence of death: how it is measured was reworded
  • DescriptionIncidence of venous thromboembolic disease: how it is measured was reworded
Nov 16, 2026
Registered
First appeared on the registry
Nov 12, 2026
Show all 2 updates
  1. Nov 16, 2026
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionIncidence of bleeding: how it is measured was reworded
    • DescriptionIncidence of death: how it is measured was reworded
    • DescriptionIncidence of venous thromboembolic disease: how it is measured was reworded
    + 3 other changes: description, arm descriptions and data sharing statement
  2. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07931053
Lead sponsor
Universidad Miguel Hernandez de Elche
Responsible party
Javier Ena (Head of Internal Medicine Division, Universidad Miguel Hernandez de Elche) — Principal investigator
First posted
Nov 12, 2026
Start date
Jan 1, 2024
Primary completion
Sep 30, 2025
Completion
Dec 30, 2025
Last update
Nov 16, 2026

Study contacts

Javier Ena, MD
principal investigator · Hospital Marina Baixa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion